Trialjectory, foundation to connect blood cancer patients with trials

By Jenni Spinner

- Last updated on GMT

(Dr_Microbe/iStock via Getty Images Plus)
(Dr_Microbe/iStock via Getty Images Plus)

Related tags Patient centricity Patient recruitment patient engagement Clinical trials Cancer Oncology

The cancer trial-matching company is partnering with MPN Research Foundation to help match patients with a group of rare blood cancers to clinical trials.

Trialjectory has announced a collaboration with the MPN Research Foundation, aimed at helping bring patients with rare blood cancers and studies in need of patients together.

MPNRF supports research into treatments for myeloproliferative neoplasms (MPNs), a set of rare blood cancers that includes essential thrombocythemia, polycythemia vera, and myelofibrosis. Trialjectory has signed up to provide the MPNRF community with its free, AI-powered clinical trial finder in a deal that could bring benefits to oncology drug developers.

Tzvia Bader, CEO, Trialjectory

This partnership will provide pharmaceutical companies with robust data and insights as a result of these patients’ participation and screenings in these clinical trials. At Trialjectory, our goal is to transform the healthcare industry and its approach to patient-centricity. By supporting enrollment in clinical trials, the pharmaceutical companies are able to examine more patient data to improve the standard of care and, in turn, create better clinical outcomes for patients​,” said Trialjectory CEO Tzvia Bader.

The clinical trial finder uses self-reported questionnaire results to provide each MPN patient with a list of studies that match their specific cancer type. Trialjectory also provides a concierge service, at no cost to patients, that enables potential study participants to get questions answered and connect directly with staff at the clinical trial site of interest.

 MPNRF CEO Kapila Viges sees Trialjectory’s capabilities as a good fit for the needs of patients with myeloproliferative neoplasms.

Kapila Viges, CEO, MPN Research Foundation

MPN patients are seeking treatment options for this family of rare blood diseases, and MPN clinical trials need patients to complete the trials with enough outcomes to demonstrate they could be made available to all patients. By providing an MPN clinical trial platform powered by Trialjectory, MPNRF can now deliver up-to-date information on clinical trials​,” Viges said.

Patients with other cancers have similar needs. Trialjectory already provides the patient match optimizer to patients with other cancers and sees the agreement with MPNRF as a model it can apply to other disease areas in the future.

Working with partners to bring their patients easy access to advanced treatment options on the sites that they are already visiting is just another streamlined efficiency we can ensure in order to eliminate stress in an already difficult time. The biggest obstacle that both oncologists and patients face is the knowledge and access to clinical trial matching. Through Trialjectory’s clinical trial finder, the process for patients is simplified​,” said Bader.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more